Microbot Medical Inc. (NASDAQ:MBOT)’s share price traded up 5.4% during trading on Thursday . The company traded as high as $1.17 and last traded at $1.17. 869,238 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 1,544,750 shares. The stock had previously closed at $1.11.
The firm’s market cap is $48.00 million. The company’s 50-day moving average price is $1.22 and its 200 day moving average price is $2.14.
Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.44. On average, analysts forecast that Microbot Medical Inc. will post ($25.02) earnings per share for the current year.
In other Microbot Medical news, Director Moshe Shoham sold 33,700 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $1.50, for a total value of $50,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Yoseph Bornstein sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $1.14, for a total transaction of $57,000.00. The disclosure for this sale can be found here. Insiders sold 424,310 shares of company stock valued at $520,396 over the last three months. Insiders own 31.83% of the company’s stock.
An institutional investor recently raised its position in Microbot Medical stock. Vanguard Group Inc. grew its holdings in Microbot Medical Inc. (NASDAQ:MBOT) by 252.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 159,992 shares of the biotechnology company’s stock after acquiring an additional 114,561 shares during the period. Vanguard Group Inc. owned 0.43% of Microbot Medical worth $228,000 as of its most recent SEC filing. 4.66% of the stock is owned by institutional investors.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.